Financial Statements

Ascendis Pharma A/S (ASND)

$84.73

+1.61 (+1.94%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) --611-393-263-
Net Income -384-419-218-130-124
Stock Dividends 3841,030---139
Dividend Paid -----
Retained Earnings ---611-393-263

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 1084543-
Annual Depreciation 42854643
Capital Expenditure -24-22-5-3-1
Net PPE 1261084543

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -3333
New Purchases ----538-226
Intangible and Goodwill 33333

Ascendis Pharma A/S income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Ascendis Pharma A/S FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.